Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

NQO1 Antikörper (C-Term)

Zitiert in 2+ Publikationen. Der Ziege Polyklonal anti-NQO1 Antikörper (ABIN374187) detektiert spezifisch NQO1 in WB und EIA. Dieser Antikörper reagiert spezifisch mit Proben aus Human, Maus, Ratte, Hund und Schwein.
Produktnummer ABIN374187
772,31 €
Zzgl. Versandkosten 20,00 € und MwSt
0.1 mg
Lieferung nach: Deutschland
Lieferung in 16 Werktagen

Kurzübersicht für NQO1 Antikörper (C-Term) (ABIN374187)

Target

Alle NQO1 Antikörper anzeigen
NQO1 (NAD(P)H Dehydrogenase, Quinone 1 (NQO1))

Reaktivität

  • 83
  • 46
  • 45
  • 3
  • 3
  • 3
  • 3
  • 2
  • 2
  • 1
Human, Maus, Ratte, Hund, Schwein

Wirt

  • 75
  • 7
  • 2
  • 1
Ziege

Klonalität

  • 59
  • 26
Polyklonal

Konjugat

  • 44
  • 4
  • 3
  • 3
  • 3
  • 3
  • 3
  • 3
  • 3
  • 2
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
Dieser NQO1 Antikörper ist unkonjugiert

Applikation

  • 66
  • 27
  • 26
  • 20
  • 19
  • 17
  • 15
  • 14
  • 14
  • 9
  • 4
  • 1
Western Blotting (WB), Enzyme Immunoassay (EIA)
  • Bindungsspezifität

    • 16
    • 8
    • 7
    • 5
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    C-Term

    Sequenz

    C-SIPTDNQIKA RK

    Spezifität

    This antibody is expected to recognize all three reported isoforms (NP_000894.1, NP_001020604.1 and NP_001020605.1) of NQO1.

    Kreuzreaktivität (Details)

    Species reactivity (expected):Rat, Pig.
    Species reactivity (tested):Human, Mouse, Canine.

    Aufreinigung

    Ammonium Sulphate Precipitation followed by Antigen Affinity Chromatography using the immunizing peptide

    Immunogen

    Peptide from C Terminus of the protein sequence according to NP_000894.1, NP_001020604.1, NP_001020605.1. Genename: NQO1
  • Applikationshinweise

    Peptide ELISA: Limit dilution 1: 64000. Western blot: 0.03-0.1 μg/mL. Approx.30 kDa band observed in Human Kidney and Lunglysates (calculated MW of 30.0 kDa according to NP_000894.1).
    Other applications not tested.
    Optimal dilutions are dependent on conditions and should be determined by the user.

    Beschränkungen

    Nur für Forschungszwecke einsetzbar
  • Konzentration

    0.5 mg/mL

    Buffer

    Tris saline, pH ~7.3 containing 0.02 % Sodium Azide as preservative and 0.5 % BSA as stabilizer

    Konservierungsmittel

    Sodium azide

    Vorsichtsmaßnahmen

    This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

    Handhabung

    Avoid repeated freezing and thawing.

    Lagerung

    4 °C/-20 °C

    Informationen zur Lagerung

    Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer.
  • Tanaka, Aleksunes, Cui, Klaassen: "ANIT-induced intrahepatic cholestasis alters hepatobiliary transporter expression via Nrf2-dependent and independent signaling." in: Toxicological sciences : an official journal of the Society of Toxicology, Vol. 108, Issue 2, pp. 247-57, (2009) (PubMed).

    Vincent, Kato, McLean, Soules, Feldman: "Sensory neurons and schwann cells respond to oxidative stress by increasing antioxidant defense mechanisms." in: Antioxidants & redox signaling, Vol. 11, Issue 3, pp. 425-38, (2009) (PubMed).

  • Target

    NQO1 (NAD(P)H Dehydrogenase, Quinone 1 (NQO1))

    Andere Bezeichnung

    NQO1

    Hintergrund

    NQO1 is a member of the NAD(P)H dehydrogenase (quinone) family and encodes a cytoplasmic 2-electron reductase. This FAD-binding protein forms homodimers and reduces quinones to hydroquinones. NQO1's enzymatic activity prevents the one electron reduction of quinones that results in the production of radical species. NQO1 functions as an important part of cellular antioxidant defense by detoxifying quinones thus preventing the formation of reactive oxygen species. Mutations in the gene for NQO1 have been associated with tardive dyskinesia (TD), an increased risk of hematotoxicity after exposure to benzene, and susceptibility to various forms of cancer. Altered expression of NQO1 has been seen in many tumors and is also associated with Alzheimer's disease (AD). NQO1 levels have been shown to be raised in may tumour types. This has led to a search for anti-tumour agents that can be activated by NQO1 resulting in specific targetting of these compounds to the tumour site. Many cytotoxic drugs contain the quinone moiety, such as the benzoquinone group, which can be activated by NQO1 through the reduction into hydroquinone [which in this case can auto-oxidize and lead to the formation of free radicals and alkylating species]. However, the rat enzyme has been shown to be significantly more effective in activating some of these compounds than the human and mouse enzymes. This indicates that the available cytotoxic drugs are better substrates for the rat enzyme and are not the most ideal prodrugs for activation by NQO1 in human tumors.Synonyms: Azoreductase, DIA4, DT-diaphorase, Menadione reductase, NAD(P)H dehydrogenase [quinone] 1, NAD(P)H:quinone oxidoreductase 1, NMOR1, Phylloquinone reductase, Quinone reductase 1

    Gen-ID

    1728

    NCBI Accession

    NP_000894

    UniProt

    P15559
Sie sind hier:
Chat with us!